-TRIMARAN and TRIGGER findings show improvements in lung function, lower exacerbation rates
Study Authors: Johann Christian Virchow, Piotr Kuna, et al.; J. Mark FitzGerald, Mohsen Sadatsafavi
Target Audience and Goal Statement: Allergists, pulmonologists, family physicians, primary care physicians
The goal of this study was to examine the outcomes from two trials that compared single-inhaler triple therapy (inhaled corticosteroid beclometasone dipropionate [BDP], long-acting beta-agonist formoterol fumarate [FF], and long-acting muscarinic antagonist glycopyrronium [G]) versus the combination of BDP with FF in uncontrolled asthma.